Helen Torley compensation by year
HALOZYME THERAPEUTICS Summary Compensation Table · all 10 fiscal years held| Component | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Salary | $645,000 | $671,000 | $725,000 | $761,000 | $791,440 | $830,221 | $871,732 | $920,000 | $960,000 | $1,000,000 |
| Bonus | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $1,799,998 | $1,900,011 | $2,115,640 | $2,184,130 | $2,500,018 | $4,060,081 | $4,950,040 | $6,200,011 | $8,840,059 | $19,350,145 |
| Option awards | $1,800,037 | $1,900,003 | $2,115,631 | $2,184,128 | $2,500,001 | $1,740,001 | $3,300,008 | $3,800,007 | $1,560,006 | $1,650,014 |
| Non-equity incentive | $595,448 | $699,115 | $831,665 | $712,296 | $712,270 | $807,619 | $557,909 | $883,476 | $1,363,392 | $1,147,500 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $9,592 | $10,422 | $11,733 | $15,572 | $15,147 | $15,372 | $17,289 | $17,364 | $17,964 | $18,564 |
| Total | $4,850,075 | $5,180,551 | $5,799,669 | $5,857,126 | $6,518,876 | $7,453,294 | $9,696,978 | $11,820,858 | $12,741,421 | $23,166,223 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: HALOZYME THERAPEUTICS, INC. DEF 14A filed March 23, 2026, accession 0001159036-26-000041, and prior-year filings. Open the filing on EDGAR.
How this page was built: the HALOZYME THERAPEUTICS, INC. filed document, accession 0001159036-26-000041. Every figure is read from that document and cited to the page and table it appears in. Filed March 23, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 96,155 | $6,471,232 | — |
| RSU | 83,785 | $5,638,731 | — |
| RSU | 67,308 | $4,529,828 | — |
| RSU | 67,027 | $4,510,917 | — |
| PSU | 51,171 | $3,443,808 | — |
| PSU | 48,245 | $3,246,889 | — |
| RSU | 33,749 | $2,271,308 | — |
| RSU | 24,984 | $1,681,423 | — |
| RSU | 21,009 | $1,413,906 | — |
| RSU | 17,858 | $1,201,843 | — |
| PSU | 8,929 | $600,922 | — |
| Option | 50,377 | — | $40.56 |
Per the Outstanding Equity Awards at Fiscal Year-End table in HALOZYME THERAPEUTICS, INC.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it. The 12 largest of 15 award rows shown.
Insider transactions since the last proxy
97 Form 4 lines since the FY2025 proxy (filed March 23, 2026)current to 2026-11-07 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-10-08 | Sale | 10b5-1 | 3,090 | $108.91 | 779,880 |
| 2026-10-08 | Sale | 10b5-1 | 11,900 | $110.00 | 767,980 |
| 2026-10-08 | Exercise or conversion | 10b5-1 | 20,000 | $18.41 | 787,780 |
| 2026-10-08 | Sale | 10b5-1 | 4,810 | $108.18 | 782,970 |
| 2026-10-08 | Sale | 10b5-1 | 200 | $110.51 | 767,780 |
| 2026-10-08 | Exercise or conversion derivative | 10b5-1 | 20,000 | $18.41 | 21,552 |
| 2026-10-07 | Sale | 10b5-1 | 900 | $112.78 | 767,980 |
| 2026-10-07 | Sale | 10b5-1 | 10,300 | $111.84 | 768,880 |
The 8 most recent of 97 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
HALOZYME THERAPEUTICS’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Helen Torley · this page | President and Chief Executive Officer | $23,166,223 |
| Nicole LaBrosse | Senior Vice President, Chief Financial Officer | $4,578,814 |
| Mark Snyder | Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary | $4,531,568 |
| Cortney Caudill | Senior Vice President, Chief Operating Officer | $3,202,906 |
| Michael LaBarre | Former Senior Vice President, Chief Technical Officer | $2,053,642 |
Board service
HALOZYME THERAPEUTICS board · FY2021–FY2025How this board is paid
Company policy: HALOZYME THERAPEUTICS pays directors a $50,000 cash retainer and $400,000 in RSUs and Options. As stated in HALOZYME THERAPEUTICS's FY2025 proxy.
The full HALOZYME THERAPEUTICS compensation record
free company briefThis page is one person within HALOZYME THERAPEUTICS's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the HALOZYME THERAPEUTICS proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order HALOZYME THERAPEUTICS's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are HALOZYME THERAPEUTICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order HALO
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.